Tonix Pharmaceuticals Files 8-K

Ticker: TNXP · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1430306

Sentiment: neutral

Topics: 8-K, financial-statements, corporate-events

Related Tickers: TNXP

TL;DR

TONX filed an 8-K on 10/7/25 - check for updates.

AI Summary

Tonix Pharmaceuticals Holding Corp. filed an 8-K on October 7, 2025, reporting on various events. The filing includes information related to financial statements and exhibits, as well as other events and a Regulation FD disclosure. The company, incorporated in Nevada, is in the pharmaceutical preparations industry.

Why It Matters

This 8-K filing provides updates on corporate events and financial information for Tonix Pharmaceuticals, which is crucial for investors to assess the company's current status and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on general corporate events and financial statements, not indicating any immediate significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Tonix Pharmaceuticals Holding Corp.?

The primary purpose of this 8-K filing is to report on various events, including Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, as of October 7, 2025.

When was Tonix Pharmaceuticals Holding Corp. incorporated and in which state?

Tonix Pharmaceuticals Holding Corp. was incorporated in Nevada.

What is the principal executive office address for Tonix Pharmaceuticals Holding Corp.?

The principal executive office address is 26 Main Street, Chatham, New Jersey, 07928.

What is the IRS Employer Identification Number for Tonix Pharmaceuticals Holding Corp.?

The IRS Employer Identification Number for Tonix Pharmaceuticals Holding Corp. is 261434750.

What is the SIC code for Tonix Pharmaceuticals Holding Corp.?

The Standard Industrial Classification (SIC) code for Tonix Pharmaceuticals Holding Corp. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 828 words · 3 min read · ~3 pages · Grade level 13.2 · Accepted 2025-10-07 08:30:31

Filing Documents

01

Item 7.01 Regulation FD Disclosure. Tonix Pharmaceuticals Holding Corp. (the "Company") updated its investor presentation, which is used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. A copy of the presentation is filed as Exhibit 99.01 hereto and incorporated herein by reference. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01

Item 8.01. Other Events. The Company intends to initiate a Phase 2 trial of its TNX-102 SL product candidate, which is already approved for the treatment of fibromyalgia, for the treatment of major depressive disorder in 2026. The Company intends to initiate an adaptive Phase 2/3 study of its TNX-4800 product candidate for the seasonal prevention of Lyme disease in 2027. Forward- Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of th

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibit No. Description. 99.01 Corporate Presentation of the Company for October 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TONIX PHARMACEUTICALS HOLDING CORP. Date: October 7, 2025 By: /s/ Bradley Saenger Bradley Saenger Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing